Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron Announces Positive Update on Recent Interactions with UK Regulatory Authorities regarding bexmarilimab and expanding the BEXMAB Study to the UK - MHRA has awarded bexmarilimab an Innovation Passport for the treatment of relapsed/refractory Myelodysplastic Syndrome and given approval for the BEXMAB trial to be conducted in the UK - UK ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Inside Information: Faron Announces Positive Phase 2 Interim Results from BEXMAB Trial to be presented at ASH Company announcement, Inside Information, 27 November 2024 Key highlights - Interim Phase 2 read-out from the BEXMAB Trial confirms earlier positive Phase 1 & 2 findings in MDS patients with prior HMA failure - In Phases 1 & 2, 20 ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Pipeline Update: Targeting Soluble Clever-1 for Autoimmune Diseases Press release, 11 November 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers and inflammation via novel immunotherapies, today announces the filing of a patent application ...
Read more
("Faron" or "the Company") Composition of Faron Pharmaceutical's Shareholders' Nomination Board Company Announcement, 5 November 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the following members have been appointed by a meeting of the ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron's Capital Markets Day 2024 - BEXMAB follow-up data and update on drug development pipeline, partnering discussions and introducing new Scientific Advisory Board Company Announcement, 22 October 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron announces Capital Markets Day to be held on 22 October 2024 Press release, 7 October 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will host a Capital Markets Day for investors, ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Grant of options Company announcement, August 30, 2024 TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that the Company's board has confirmed the grant of a total of 100,000 options over new ordinary ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or "the Company") Faron Reports Half-Year Financial Results, 1 January - 30 June 2024 Company Announcement, 27 August 2024 Summary Highlights Initial preliminary phase II data read-out from the BEXMAB trial confirmed earlier positive phase I findings in myelodysplastic syndrome (MDS) patients that have failed with hypomethylating agent (HMA), reinforcing ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or the "Company") Inside Information: FDA Grants Fast Track Designation for Bexmarilimab in r/r MDS Company announcement, Inside Information, 26 August 2024 at 7:00 a.m. BST / 9:00 a.m. EEST Key highlights - Given the strong data seen in Phase 1 and continuing in Phase 2 of Faron's BEXMAB trial, the FDA has granted Fast Track Designation (FTD) for ...
Read more
Faron Pharmaceuticals Ltd. ("Faron" or the "Company") Faron Pharmaceuticals Notice of Half-Year Financial Results Company Announcement, 20 August 2024 TURKU, Finland - Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor ...
Read more